Renal function, glucose and LDH assessment of COVID-19 patients

Sara Jassim  Mohammed; Falah S. AL-Fartusie; Ahmed Jasim Mohammed Gawi

doi:10.53730/ijhs.v6nS5.9622

Authors

Sara Jassim Mohammed Department of Chemistry, College of Science, Al-Mustansiriyah University, Baghdad, Iraq
Falah S. AL-Fartusie
sci.falah.al_fartusie@uomustansiriyah.edu.iq
Department of Chemistry, College of Science, Al-Mustansiriyah University, Baghdad, Iraq
Ahmed Jasim Mohammed Gawi MOH, Ibn-Alkuff Hospital for Spinal Cord Injury, Baghdad-Iraq

Keywords:

COVID 19, Renal Functiont, Lactic Dehydrogenase, glucose

Abstract

Corona viruses are members of the order nidovirales and the corona family. Coronaviruses (CoVs) are a family of closed-cell, positive-sense, single-stranded RNA viruses with a wide range of characteristics. They produce a variety of health problems in humans and animals and affect the respiratory, digestive, liver and nervous systems. In this study, kidney function tests, LDH and glucose were evaluated in COVID-19 patients. The study included 120 cases, who were divided into three groups; a first group of 40 patients with COVID-19, and the secondgroup of 40 recovered of COVID 19, and the third group was control of40. The results indicated a significant increase (P < 0.01) in the renal function parameters of Covid-19 patients compared to the recovered and control groups. The obtained results also indicated a significant increase in LDH and glucose levels (P<0.01) in patients compared to the recoverdand control values. Among these results, it appears that the Corona virus may affect and threateneverything that cause the failure of vital organs in the body.

Downloads

Download data is not yet available.

References

Z. Wu and J. M. McGoogan, “Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention,” Jama, vol. 323, no. 13, pp. 1239–1242, 2020.

T. M. Abd El-Aziz and J. D. Stockand, “Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status,” Infect. Genet. Evol., vol. 83, p. 104327, 2020.

J. Machhi et al., “The natural history, pathobiology, and clinical manifestations of SARS-CoV-2 infections,” J. Neuroimmune Pharmacol., pp. 1–28, 2020.

R. Dhand and J. Li, “Coughs and sneezes: their role in transmission of respiratory viral infections, including SARS-CoV-2,” Am. J. Respir. Crit. Care Med., vol. 202, no. 5, pp. 651–659, 2020.

R. Tellier, Y. Li, B. J. Cowling, and J. W. Tang, “Recognition of aerosol transmission of infectious agents: a commentary,” BMC Infect. Dis., vol. 19, no. 1, pp. 1–9, 2019.

W. Y. T. Tan, L. Y. Wong, Y. S. Leo, and M. Toh, “Does incubation period of COVID-19 vary with age? A study of epidemiologically linked cases in Singapore,” Epidemiol. Infect., vol. 148, 2020.

T. Wise, T. D. Zbozinek, G. Michelini, C. C. Hagan, and D. Mobbs, “Changes in risk perception and self-reported protective behaviour during the first week of the COVID-19 pandemic in the United States,” R. Soc. open Sci., vol. 7, no. 9, p. 200742, 2020.

E. Ciaglia, C. Vecchione, and A. A. Puca, “COVID-19 infection and circulating ACE2 levels: protective role in women and children,” Front. Pediatr., vol. 8, p. 206, 2020.

P.-I. Lee, Y.-L. Hu, P.-Y. Chen, Y.-C. Huang, and P.-R. Hsueh, “Are children less susceptible to COVID-19?,” J. Microbiol. Immunol. Infect., vol. 53, no. 3, p. 371, 2020.

E. N. Perencevich, D. J. Diekema, and M. B. Edmond, “Moving personal protective equipment into the community: face shields and containment of COVID-19,” Jama, vol. 323, no. 22, pp. 2252–2253, 2020.

A. Tahamtan and A. Ardebili, “Real-time RT-PCR in COVID-19 detection: issues affecting the results,” Expert Rev. Mol. Diagn., vol. 20, no. 5, pp. 453–454, 2020.

W. Hao and M. Li, “Clinical diagnostic value of CT imaging in COVID-19 with multiple negative RT-PCR testing,” Travel Med. Infect. Dis., vol. 34, p. 101627, 2020.

L. H. Kahn, Who’s In charge? Leadership during epidemics, bioterror attacks, and other public health crises. ABC-CLIO, 2020.

A. Gasmi, S. Noor, T. Tippairote, M. Dadar, A. Menzel, and G. Bjørklund, “Individual risk management strategy and potential therapeutic options for the COVID-19 pandemic,” Clin. Immunol., vol. 215, p. 108409, 2020.

D. Spiegelhalter, “Use of ‘normal’ risk to improve understanding of dangers of covid-19,” bmj, vol. 370, 2020.

G. Sharma, A. S. Volgman, and E. D. Michos, “Sex differences in mortality from COVID-19 pandemic: are men vulnerable and women protected?,” Case Reports, vol. 2, no. 9, pp. 1407–1410, 2020.

A. Capuano, F. Rossi, and G. Paolisso, “Covid-19 kills more men than women: an overview of possible reasons,” Front. Cardiovasc. Med., vol. 7, p. 131, 2020.

E. Puchhammer-Stöckl, S. W. Aberle, and H. Heinzl, “Association of age and gender with alphaherpesvirus infections of the central nervous system in the immunocompetent host,” J. Clin. Virol., vol. 53, no. 4, pp. 356–359, 2012.

A. Ruggieri, M. C. Gagliardi, and S. Anticoli, “Sex-dependent outcome of hepatitis B and C viruses infections: synergy of sex hormones and immune responses?,” Front. Immunol., p. 2302, 2018.

F. Ok, O. Erdogan, E. Durmus, S. Carkci, and A. Canik, “Predictive values of blood urea nitrogen/creatinine ratio and other routine blood parameters on disease severity and survival of COVID‐19 patients,” J. Med. Virol., vol. 93, no. 2, pp. 786–793, 2021.

S. M. Moledina et al., “Clinical characteristics and predictors of mortality in patients with COVID-19 infection outside intensive care,” Int. J. Gen. Med., vol. 13, p. 1157, 2020.

Y. Cheng et al., “Kidney impairment is associated with in-hospital death of COVID-19 patients,” MedRxiv, 2020.

G. A. de Erausquin, H. Snyder, M. Carrillo, A. A. Hosseini, T. S. Brugha, and S. Seshadri, “The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning,” Alzheimer’s Dement., vol. 17, no. 6, pp. 1056–1065, 2021.

S. Papachristou, I. Stamatiou, A. P. Stoian, and N. Papanas, “New-onset diabetes in COVID-19: time to frame its fearful symmetry,” Diabetes Ther., vol. 12, no. 2, pp. 461–464, 2021.

B. Wang, R. Li, Z. Lu, and Y. Huang, “Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis,” Aging (albany NY), vol. 12, no. 7, p. 6049, 2020.

W. Guan, “J., Ni, Z,” Y., Hu, YU, Liang, W.‐H., Ou, C.‐Q., He, J.‐X., Liu, L., Shan, H., Lei, C.‐L., Hui, DSC, Du, B., Li, L.‐J., Zeng, G., Yuen, K.‐Y., Chen, pp. 1708–1720, 2020.

L. Szarpak et al., “Lactate dehydrogenase level as a COVID-19 severity marker,” Am. J. Emerg. Med., 2020.

Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). The COVID-19 pandemic. International Journal of Health Sciences, 5(2), vi-ix. https://doi.org/10.53730/ijhs.v5n2.2937

Abbas HA, Alsaade KA, AlMAshhdan HA. Study the effect of cyperus rotundus extracted as mouthwash on the corrosion of dental amalgam. InIOP Conference Series: Materials Science and Engineering 2019 Jul 1 (Vol. 571, No. 1, p. 012074). IOP Publishing.

A. Farhana and S. L. Lappin, “Biochemistry, lactate dehydrogenase,” StatPearls [Internet], 2021.

L. Fiume, M. Manerba, M. Vettraino, and G. Di Stefano, “Inhibition of lactate dehydrogenase activity as an approach to cancer therapy,” Future Med. Chem., vol. 6, no. 4, pp. 429–445, 2014.

M. Wu et al., “Clinical evaluation of potential usefulness of serum lactate dehydrogenase (LDH) in 2019 novel coronavirus (COVID-19) pneumonia,” Respir. Res., vol. 21, no. 1, pp. 1–6, 2020.

Wahyuni, S., Chalid, S. M. T., Pelupessy, N. U., Arifuddin, S., Idris, I., & Usman, A. N. (2022). Comparison of the use of shock index and modified early obstetric warning score in COVID-19 obstetric emergency patients as ICU care parameters. International Journal of Health & Medical Sciences, 5(1), 80-90. https://doi.org/10.21744/ijhms.v5n1.1844